1074-86-8 Usage
Description
Indole-4-carboxaldehyde is an organic compound that serves as a synthetic intermediate in various chemical and pharmaceutical applications. It is a white to dark brown solid and is known for its involvement in the synthesis of arcyriacyanin A. The compound has been reported to undergo intramolecular Friedel-Crafts acylation.
Uses
Indole-4-carboxaldehyde is used in multiple applications across different industries, primarily as a reactant in various chemical reactions and pharmaceutical synthesis.
Used in Pharmaceutical Synthesis:
Indole-4-carboxaldehyde is used as a synthetic intermediate for the preparation of antitumor agents, contributing to the development of cancer treatments.
Used in Biginelli Reaction:
In the field of organic chemistry, Indole-4-carboxaldehyde is used as a reactant in the Biginelli reaction, which is a multicomponent reaction for the synthesis of dihydropyrimidinones.
Used in the Synthesis of Aurora Kinase A Inhibitors:
Indole-4-carboxaldehyde is utilized in the synthesis of aurora kinase A inhibitors, which are important in the development of targeted cancer therapies.
Used in Intramolecular Friedel-Crafts Acylation:
The compound is also used in intramolecular Friedel-Crafts acylation, a chemical reaction that involves the formation of a cyclic compound through the acylation of an aromatic ring.
Used in the Preparation of Inhibitors of Cell Division in E. Coli:
Indole-4-carboxaldehyde is employed in the preparation of inhibitors that prevent cell division in E. coli, which can have implications in the study of bacterial growth and antibiotic development.
Used in the Synthesis of Hantzsch Pyridine-Containing Schiff Bases:
The compound is also used in the synthesis of Hantzsch pyridine-containing Schiff bases, which are important in the field of coordination chemistry and have potential applications in various areas, including catalysis and medicinal chemistry.
Synthesis Reference(s)
The Journal of Organic Chemistry, 46, p. 1752, 1981 DOI: 10.1021/jo00321a053Tetrahedron, 39, p. 3695, 1983 DOI: 10.1016/S0040-4020(01)88608-7
Check Digit Verification of cas no
The CAS Registry Mumber 1074-86-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,0,7 and 4 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1074-86:
(6*1)+(5*0)+(4*7)+(3*4)+(2*8)+(1*6)=68
68 % 10 = 8
So 1074-86-8 is a valid CAS Registry Number.
InChI:InChI=1/C9H7NO/c11-6-7-2-1-3-9-8(7)4-5-10-9/h1-6,10H
1074-86-8Relevant articles and documents
Synthesis of indole-4-carboxaldehydes and 4-Acetylindole from N-alkyl-5-aminoisoquinolinium salts
Muchowski
, p. 1293 - 1297 (2000)
N-Alkyl-5-aminoisoquinolinium salts (8a-d) are converted into indole-4-carboxaldehydes (1a-c) on heating in a two phase alkyl acetate-water system containing an excess of a 2:1 sodium bisulfite-sodium sulfite mixture, 4-Acetylindole 1e is prepared in the same way from 1-methyl-2-cyanomethylisoquinolinium bromide 8f.
Dopamine receptor ligands. Part 18: Modification of the structural skeleton of indolobenzazecine-type dopamine receptor antagonists
Robaa, Dina,Enzensperger, Christoph,El Din Abul Azm, Shams,El Khawass, El Sayeda,El Sayed, Ola,Lehmann, Jochen
supporting information; experimental part, p. 2646 - 2650 (2010/08/19)
On the basis of the D1/5-selective dopamine antagonist LE 300 (1), an indolo[3,2-f]benzazecine derivative, we changed the annulation pattern of the heterocycles. The target compounds represent novel heterocyclic ring systems. The most constrained indolo[4,3a,3-ef]benzazecine 2 was inactive, but the indolo[4,3a,3-fg]benzazacycloundecene 3 showed antagonistic properties (functional Ca2+ assay) with nanomolar affinities (radioligand binding) for all dopamine receptor subtypes, whereas the indolo[2,3-f] benzazecine 4 displayed a selectivity profile similar to 3 but with decreased affinities.
Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
-
Page/Page column 20, (2010/11/08)
The present invention relates to a method of treating disorders including cognition impairment, generalized anxiety disorder, acute stress disorder, social phobia, simple phobias, pre-menstrual dysphoric disorder, social anxiety disorder, major depressive
